
Attgeno, home of Supernitro, is a Swedish clinical stage pharmaceutical company founded by a research group at the Karolinska Institute, Stockholm, to develop and bring to market new nitric oxide (NO)-donating technology and products. Our first drug candidate, Supernitro, is based on a novel principle developed by Attgeno and is intended to reverse life-threatening high blood pressure in the lungs (acute pulmonary hypertension, aPH).
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.